Marie R McCausland1, Angélica Cruz-Lebrón1, Heather A Pilch-Cooper2, Scott Howell3, Jeffrey M Albert4, Young S Park5, Alan D Levine1,6. 1. Department of Molecular Biology and Microbiology. 2. Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University School of Medicine. 3. Department of Ophthalmology, University Hospitals Cleveland Medical Center. 4. Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. 5. Department of Pathology, Asian Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 6. Departments of Medicine, Pediatrics, Pathology, and Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Abstract
DESIGN: Since intestinal immunity and the microbiome are disrupted in HIV disease, we studied the abundance of innate immune sensors, Toll-like receptors (TLRs), in the mucosa of participants with viremia, prior to antiretroviral therapy (ART), immune success (>500 CD4 T cells/μl after 2 years of ART; suppressed viremia), and immune failure (<350 CD4 T cells/μl after 2 years of ART; suppressed viremia). We hypothesized that disruption of intestinal TLR abundance and location provides a mechanism behind persistent inflammation. METHODS: Immunofluorescence for TLR3, TLR4, and TLR9 on paraffin embedded biopsies from uninfected, viremic, immune success, and immune failure colons was imaged by deconvolution microscopy and quantified with MetaMorph software. Plasma levels of C-reactive protein, IL-6, and intestinal fatty-acid binding protein (I-FABP) were correlated with TLR expression. RESULTS: Viremic participants have significantly higher levels of TLR3 and TLR9 on surface epithelium and in crypts when compared with uninfected controls. TLR3 is further elevated in immune failure and immune success. TLR9 abundance remains elevated in immune failure and is normalized in immune success. TLR9 expression in the crypt and lamina propria positively associates with C-reactive protein and IL-6 and negatively with I-FABP. TLR4 is significantly lower on surface epithelium and higher in crypts in viremic. Its expression in the lamina propria positively correlates with IL-6 and negatively correlates with I-FABP. CONCLUSION: Mucosal TLR imbalance and deregulation, and the resulting mucosal TLR desensitization and hypervigilance, remain after suppressive ART, in the presence or absence of T-cell recovery, likely contributing to chronic systemic inflammation.
DESIGN: Since intestinal immunity and the microbiome are disrupted in HIV disease, we studied the abundance of innate immune sensors, Toll-like receptors (TLRs), in the mucosa of participants with viremia, prior to antiretroviral therapy (ART), immune success (>500 CD4 T cells/μl after 2 years of ART; suppressed viremia), and immune failure (<350 CD4 T cells/μl after 2 years of ART; suppressed viremia). We hypothesized that disruption of intestinal TLR abundance and location provides a mechanism behind persistent inflammation. METHODS: Immunofluorescence for TLR3, TLR4, and TLR9 on paraffin embedded biopsies from uninfected, viremic, immune success, and immune failure colons was imaged by deconvolution microscopy and quantified with MetaMorph software. Plasma levels of C-reactive protein, IL-6, and intestinal fatty-acid binding protein (I-FABP) were correlated with TLR expression. RESULTS: Viremic participants have significantly higher levels of TLR3 and TLR9 on surface epithelium and in crypts when compared with uninfected controls. TLR3 is further elevated in immune failure and immune success. TLR9 abundance remains elevated in immune failure and is normalized in immune success. TLR9 expression in the crypt and lamina propria positively associates with C-reactive protein and IL-6 and negatively with I-FABP. TLR4 is significantly lower on surface epithelium and higher in crypts in viremic. Its expression in the lamina propria positively correlates with IL-6 and negatively correlates with I-FABP. CONCLUSION: Mucosal TLR imbalance and deregulation, and the resulting mucosal TLR desensitization and hypervigilance, remain after suppressive ART, in the presence or absence of T-cell recovery, likely contributing to chronic systemic inflammation.
Authors: Colleen F Kelley; Christina M R Kitchen; Peter W Hunt; Benigno Rodriguez; Frederick M Hecht; Mari Kitahata; Heide M Crane; James Willig; Michael Mugavero; Michael Saag; Jeffrey N Martin; Steven G Deeks Journal: Clin Infect Dis Date: 2009-03-15 Impact factor: 9.079
Authors: Robin M Voigt; Ali Keshavarzian; John Losurdo; Garth Swanson; Basile Siewe; Christopher B Forsyth; Audrey L French; Patricia Demarais; Phillip Engen; Shohreh Raeisi; Ece Mutlu; Alan L Landay Journal: AIDS Date: 2015-03-13 Impact factor: 4.177
Authors: Michael M Lederman; Nicholas T Funderburg; Rafick P Sekaly; Nichole R Klatt; Peter W Hunt Journal: Adv Immunol Date: 2013 Impact factor: 3.543
Authors: Tae-Wook Chun; David C Nickle; Jesse S Justement; Jennifer H Meyers; Gregg Roby; Claire W Hallahan; Shyam Kottilil; Susan Moir; Joann M Mican; James I Mullins; Douglas J Ward; Joseph A Kovacs; Peter J Mannon; Anthony S Fauci Journal: J Infect Dis Date: 2008-03-01 Impact factor: 5.226
Authors: Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek Journal: Nat Med Date: 2006-11-19 Impact factor: 53.440
Authors: Sandeep K Agarwal; Minghua Wu; Christopher K Livingston; Donald H Parks; Maureen D Mayes; Frank C Arnett; Filemon K Tan Journal: Arthritis Res Ther Date: 2011-01-11 Impact factor: 5.156
Authors: Maarten Schurink; Elisabeth M W Kooi; Christian V Hulzebos; Rozemarijn G Kox; Henk Groen; Erik Heineman; Arend F Bos; Jan B F Hulscher Journal: PLoS One Date: 2015-03-20 Impact factor: 3.240
Authors: Ashley Canipe; Takondwa Chidumayo; Meridith Blevins; Michael Bestawros; Jay Bala; Paul Kelly; Suzanne Filteau; Bryan E Shepherd; Douglas C Heimburger; John R Koethe Journal: BMC Infect Dis Date: 2014-09-29 Impact factor: 3.090